The researchers introduced atezolizumab-based PD-L1-targeted CAR into T cells, and the combination of HER2-CAR T cells and PD-L1-CAR T cells showed significant benefits against breast cancer MCF-7 cells [35]. This evidence concerns the gene CD274 and breast carcinoma.